2017

Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy

APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer

SOLE (Study of Letrozole Extension):A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer

Primary results of LORELEI study presentedat ESMO 2017 Congress

PANACEA study suggests immunotherapy may help to overcome trastuzumab-resistant breast cancer

Ovarian Suppression Reduces Recurrence for Young Breast Cancer Patients

Breast International Group (BIG) – aisbl

Head Office

Tax Deduction

Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.

Site Links

The Breast International Group is proud to adhere to the Code of Ethics of the RE-EF.

Co-funded by the European Union under an operating grant from the European Union’s EU4Health programme under grant agreement No 101124555. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

EN FR NL